Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

• Published in: Clinical pharmacokinetics Vol. 49; no. 8; pp. 493 - 507
• Main Authors: Keizer, Ron J., Huitema, Alwin D. R., Schellens, Jan H. M., Beijnen, Jos H.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.08.2010; Adis International; Wolters Kluwer Health, Inc; Springer Nature B.V
• Subjects: Absorption; Animals; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal - therapeutic use; Biological and medical sciences; Complications and side effects; Dosage and administration; Drug Administration Routes; Drug Interactions; General pharmacology; Humans; Immunologic Factors - administration & dosage; Immunologic Factors - pharmacokinetics; Immunologic Factors - therapeutic use; Internal Medicine; Licensing, certification and accreditation; Medical sciences; Medicine; Medicine & Public Health; Mice; Mice, Knockout; Monoclonal antibodies; Pharmacokinetics; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions; Pharmacology. Drug treatments; Pharmacology/Toxicology; Pharmacotherapy; Review Article; Tissue Distribution; Abciximab; Infliximab; Human Epidermal Growth Factor Receptor; Trastuzumab; Ranibizumab; Human; Treatment; Monoclonal antibody; Pharmacokinetics

Monoclonal antibodies (mAbs) have been used in the treatment of various diseases for over 20 years and combine high specificity with generally low toxicity. Their pharmacokinetic properties differ markedly from those of non-antibody-type drugs, and these properties can have important clinical implic...